BTIG Reiterates Buy on Hyperfine, Maintains $2 Price Target
9/22/2026
Impact: 70
Healthcare
BTIG analyst Marie Thibault has reiterated a Buy rating on Hyperfine (NASDAQ: HYPR) and maintained a price target of $2 for the stock. This recommendation reflects confidence in the company's performance and potential growth.
AI summary, not financial advice
Share: